Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1)
Latest Information Update: 29 Apr 2025
At a glance
- Drugs Bepirovirsen (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Acronyms B Well 1
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
Most Recent Events
- 24 Apr 2025 Planned primary completion date changed from 24 Nov 2025 to 12 Nov 2025.
- 03 Jun 2024 Planned End Date changed from 1 Apr 2026 to 8 May 2026.
- 03 Jun 2024 Planned primary completion date changed from 15 Oct 2025 to 24 Nov 2025.